Activating point mutations of RET proto-oncogene have been demonstrated to be causative of the familial form of medullary thyroid cancer, both as isolated FMTC and associated to MEN 2A and 2B [2]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.